Acrivon Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $848 | $0 |
Gross Profit | -300 | -311 | -303 | -300 |
EBITDA | -22,649 | -19,369 | -24,651 | -24,889 |
EBIT | -22,949 | -19,680 | -24,954 | -25,189 |
Net Income | -21,006 | -19,680 | -22,831 | -22,441 |
Net Change In Cash | 0 | 0 | 848 | 0 |
Free Cash Flow | -17,103 | -19,593 | -18,187 | -18,312 |
Cash | 41,895 | 39,154 | 39,818 | 43,415 |
Basic Shares | 38,461 | 38,350 | 38,242 | 38,105 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,006 | -536 | -1,095 | -832 |
EBITDA | -79,550 | -59,852 | -32,293 | -15,411 |
EBIT | -80,556 | -60,388 | -32,657 | -16,243 |
Net Income | -80,556 | -60,388 | -29,677 | -16,243 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -70,084 | |||
Free Cash Flow | -68,437 | -43,929 | -32,283 | -14,220 |
Cash | 39,818 | 36,015 | 29,519 | 99,603 |
Basic Shares | 337,918 | 22,078 | 21,920 | 20,859 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.55 |
2025-03-31 | -$0.51 |
2024-12-31 | -$0.60 |
